BioLineRX stem cell leukemia drug meets goals in early trial

March 25, 2015 11:57 AM

14 0

JERUSALEM (Reuters) - Israeli biopharmaceutical company BioLineRX Ltd said on Wednesday an early stage trial for a drug that uses stem cells to treat leukemia and other blood cancers met all safety and efficacy goals.

Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its treatment, currently called BL-8040, needed just one.

Also read: Bold predictions for all 31 NHL teams at the trade deadline

Read more

To category page